摘要
目的:评价HMG-CoA还原酶抑制剂辛伐他汀对血脂正常及血脂异常的糖尿病肾病(diabeticnephropathy,DN)防治效果,并探讨相应作用机制。方法:采用随机、对照研究,观察辛伐他汀治疗前后血脂升高及正常的DN患者尿微量白蛋白排泄率以及尿转化生长因子1β(TGF-1β)、层黏连蛋白(LAM)和IV型胶原(CIV)的变化。结果:辛伐他汀治疗6个月后,血脂正常及异常组患者尿微量白蛋白排泄率(0.032±0.041及0.066±0.074g/24h),尿TGF-1β(1.41±1.15及1.74±1.55μg/L)、LAM(15.86±11.21及11.52±7.21μg/L)和CIV(20.25±16.56及21.44±17.05μg/L)均较治疗前有显著降低,P<0.05,而对照组则较基线值明显升高。结论:辛伐他汀可以抑制肾脏TGF-1β、LAM及CIV的表达、有效地降低糖尿病肾病患者尿蛋白的排出,从而发挥其肾脏保护作用。
Objective： To investigate the effect of simvastatin on the patients with diabetic nephropathy （DN）. Methods： Patients with DN were randomly assigned into control group and simvastatin treated group. Urinary microalbuminuria, TGFβ1, type Ⅳ collagen and laminin were detected at baseline and six months later. Results： The urinary microalbuminuria were 0.032 ± 0.041 and 0.066 ± 0.074 g/24h, and 24 h-TGFβ1 were 1.41 ± 1.15 and 1.74 ± 1.55 μg/L, and 24 htype Ⅳ collagen were 20.25 ± 16.56 and 21.44 ± 17.05 μg/L, and 24 h-laminin were 15.86 ± 11.21 and 11.52 ± 7.21 μg/L in simvastatin-treated groups with orwithout dyslipidemia. Conclusion： Simvastatin can prevent the development of diabetic nephropathy through inhibiting the secretion of TGF-β, type Ⅳ collagen and laminin.
出处
《南京医科大学学报（自然科学版）》
CAS
CSCD
北大核心
2006年第7期582-584,共3页
Journal of Nanjing Medical University(Natural Sciences)
基金
中央保健委员会办公室专项资金资助(苏B047)
